Diethylpropion and mazindol: An end to the discussion?

• Type: Article in International Scientific Journal
• Date: 2017

Authors

Lucchetta, RC (Author) Other; Riveros, BS (Author) Other; Pontarolo, R (Author) Other; Radominski, RB (Author) Other; Otuki, MF (Author) Other; Fernandez Llimos, F (Author) Other; Correr, CJ (Author) Other

Journal

Title: Revista da Associacao Medica Brasileira

Vol. 63

Pages: 203-206

ISSN: 0104-4230

Publisher: Elsevier

Indexing

Scopus - 3 Citations

Other information

Authenticus ID: P-00M-V3R

DOI: 10.1590/1806-9282.63.03.203

Abstract (EN): Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitáia) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.

Language: English

Type (Professor's evaluation): Scientific